Previous Close | 1.3000 |
Open | 1.3400 |
Bid | 1.2800 x 1000 |
Ask | 1.3400 x 900 |
Day's Range | 1.2700 - 1.3500 |
52 Week Range | 0.8360 - 4.6500 |
Volume | |
Avg. Volume | 565,312 |
Market Cap | 59.937M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9620 |
Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ZYNE
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorders, FXS and 22q $62.5 million in cash and cash equivalents at June 30, 2022; Cash runway through the end of 2023 / early 2024 DEVON, Pa., Aug. 10, 2022 (GLOBE N
DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present an overview and update of the Company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 9:00 a.m. ET at the InterContinental Boston
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...